

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF
02 MAY 30 F

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) – All Filers Are Required To Complete This Page

1. Registrant Name

Ernst & Young LLP

2. Address ☐ Check if different than previously reported

1225 Connecticut Avenue, NW

3. Principal Place of Business (if different from line 2)

City: **Washington, DC**

State/Zip (or Country) **20036**

4. Contact Name

Telephone

E-mail (optional)

5. Senate ID #

Tom S. Neubig

(202) 327-8817

None Assigned Yet

7. Client Name

☐ Self

6. House ID #

Pharmaceutical Research and Manufacturers of America

None Assigned Yet

TYPE OF REPORT 8. Year 2001 Mid-year (January 1–June 30) ☐ OR Year End (July 1–December 31) ☐

9. Check if this filing amends a previously filed version of this report ☐

10 Check if this is a Termination Report ☒ ⇒ Termination Date December 31, 2001 11. No Lobbying Activities ☐

INCOME OR EXPENSES – Complete Either Line 12 OR Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000 ☐

\$10,000 or more ☒ ⇒ \$ 10,000
Income (nearest \$20,000)

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this period were:

Less than \$10,000 ☐

\$10,000 or more ☐ ⇒ \$ _____
Expenses (nearest \$20,000)

14. REPORTING METHOD. Check box to indicate accounting method. See instructions for descriptions.

☐ Method A. Reporting amounts using LDA (Internal Revenue Code)

☐ Method B. Reporting amounts under section 162(e) of the Internal Revenue Code

☐ Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature

TS Neubig

Printed Name and Title **Thomas S. Neubig, Partner**

15 General issue area code MED (one per page)

16. Specific lobbying issues

Issues related to the cost of conducting research & development by pharmaceutical companies.

17. House(s) of Congress and Federal agencies contacted ☒ Check if None

18. Name of each individual who acted as a lobbyist in this issue area

[illegible]

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Signature 125 New Date January 15, 2002

Printed Name and Title **Thomas S. Neubig, Partner**

